1 / 22

Pandemic Influenza Vaccine Supply Issues April 20, 2005

Presentation Outline. Pandemic Vaccine Supply and Timelines (some reminders from yesterday's and today's discussions)Current status of vaccine supplyPotential expansion of vaccine supplyCapacity increaseAntigen-sparing approaches. Pandemic Influenza Vaccine Production Timelines. Development of

ron
Download Presentation

Pandemic Influenza Vaccine Supply Issues April 20, 2005

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Pandemic Influenza Vaccine Supply Issues April 20, 2005 Raymond A. Strikas, M.D. National Immunization Program, Centers for Disease Control and Prevention I�m going to talk about Effective Immunization Interventions, and will focus mainly on adults. The findings I will be discussing are based mainly on a review of the literature that was conducted as part of the Guide to Community Preventive Services vaccine chapter.I�m going to talk about Effective Immunization Interventions, and will focus mainly on adults. The findings I will be discussing are based mainly on a review of the literature that was conducted as part of the Guide to Community Preventive Services vaccine chapter.

    2. Presentation Outline Pandemic Vaccine Supply and Timelines (some reminders from yesterday�s and today�s discussions) Current status of vaccine supply Potential expansion of vaccine supply Capacity increase Antigen-sparing approaches

    3. Pandemic Influenza Vaccine Production Timelines Development of reference strain Use of reverse genetics allows HA and NA from pandemic strain to be combined with other genes from a strain well adapted to growth in eggs Vaccine production (monovalent) Master seed developed from reference strain Growth in eggs and purification Formulation and filling Regulatory process Optimal timing ~3-4 months (if reference strain and potency testing reagents already developed)

More Related